PMID- 35608188 OWN - NLM STAT- MEDLINE DCOM- 20221230 LR - 20221230 IS - 1468-3083 (Electronic) IS - 0926-9959 (Linking) VI - 36 IP - 11 DP - 2022 Nov TI - The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis. PG - 1937-1946 LID - 10.1111/jdv.18263 [doi] AB - Janus kinase (JAK) inhibitors are novel treatment approaches for psoriasis. However, there is no direct comparison of JAK inhibitors in plaque psoriasis. In order to compare the efficacy and safety of JAK inhibitors in psoriasis, we conducted a network meta-analysis using eligible randomized clinical trials (RCTs). The efficacy of JAK inhibitors was evaluated using a 75% improvement in Psoriasis Area and Severity Index (PASI75) from baseline, and the proportion of patients achieving the Physician's Global Assessment (PGA) response. The incidence of treatment-related adverse events (AEs) was also assessed. A total of eight RCTs with tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib were included. A total of 3612 participants who were diagnosed with moderate-to-severe plaque psoriasis were analysed. Overall, JAK inhibitors showed superior PASI75 response over placebo at both 8 and 12 weeks. Among all included JAK inhibitors, tofacitinib 15 mg twice a day (BID) had the highest probability of achieving PASI75 at both 8 and 12 weeks (SUCRA = 0.938 and 0.937, separately), followed by tofacitinib 10 mg BID (SUCRA = 0.905 and 0.908, separately) and deucravacitinib 12 mg once daily (QD) (SUCRA = 0.874 and 0.837, separately). A similar finding was observed for PGA response. Safety assessment showed that all JAK inhibitors had non-inferior safety compared with placebo, except for deucravacitinib 6 mg BID and 12 mg QD. Tofacitinib 2 mg BID was the first-ranked drug for safety profile followed by deucravacitinib 3 mg QD, and tofacitinib 5 mg BID. When comprehensively evaluated the efficacy and safety, tofacitinib (2 mg, 5 mg, 10 mg, 15 mg BID) was superior to other included JAK inhibitors with satisfying PASI75 and PGA response, as well as relatively low incidence of AEs. Our study confirmed that JAK inhibitors had promising treatment efficacy for moderate-to-severe plaque psoriasis. Tofacitinib showed superior efficacy and safety over peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib. CI - (c) 2022 European Academy of Dermatology and Venereology. FAU - Zhang, L AU - Zhang L AUID- ORCID: 0000-0001-8400-5228 AD - Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China. AD - Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology (CIII), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China. FAU - Guo, L AU - Guo L AD - Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China. AD - Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology (CIII), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China. FAU - Wang, L AU - Wang L AD - Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China. AD - Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology (CIII), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China. FAU - Jiang, X AU - Jiang X AUID- ORCID: 0000-0001-5109-6055 AD - Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China. AD - Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology (CIII), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China. LA - eng GR - ZYJC21036/The 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University/ GR - ZYJC21036/West China Hospital, Sichuan University/ GR - NSFC 81872535/National Natural Science Foundation of China/ GR - NSFC 82073473/National Natural Science Foundation of China/ PT - Journal Article PT - Meta-Analysis PT - Review DEP - 20220609 PL - England TA - J Eur Acad Dermatol Venereol JT - Journal of the European Academy of Dermatology and Venereology : JEADV JID - 9216037 RN - 73SM5SF3OR (abrocitinib) RN - PJY633525U (Adamantane) RN - 0 (Azetidines) RN - ISP4442I3Y (baricitinib) RN - N0A21N6RAU (deucravacitinib) RN - 0 (Heterocyclic Compounds) RN - 0 (Immunosuppressive Agents) RN - 0 (Janus Kinase Inhibitors) RN - EC 2.7.10.2 (Janus Kinases) RN - 25X51I8RD4 (Niacinamide) RN - HPH1166CKX (peficitinib) RN - 0 (Piperidines) RN - 0 (Protein Kinase Inhibitors) RN - 0 (Purines) RN - 0 (Pyrazoles) RN - 0 (Pyrimidines) RN - 0 (Sulfonamides) RN - 87LA6FU830 (tofacitinib) SB - IM MH - Humans MH - Adamantane/adverse effects/analogs & derivatives MH - Azetidines/adverse effects MH - Heterocyclic Compounds/adverse effects MH - Immunosuppressive Agents/adverse effects MH - *Janus Kinase Inhibitors/adverse effects MH - Janus Kinases MH - Network Meta-Analysis MH - Niacinamide/adverse effects/analogs & derivatives MH - Piperidines MH - Protein Kinase Inhibitors/adverse effects MH - *Psoriasis/drug therapy MH - Purines/adverse effects MH - Pyrazoles/adverse effects MH - Pyrimidines/adverse effects MH - Sulfonamides/adverse effects MH - Treatment Outcome EDAT- 2022/05/25 06:00 MHDA- 2022/10/15 06:00 CRDT- 2022/05/24 07:04 PHST- 2021/06/23 00:00 [received] PHST- 2022/04/21 00:00 [accepted] PHST- 2022/05/25 06:00 [pubmed] PHST- 2022/10/15 06:00 [medline] PHST- 2022/05/24 07:04 [entrez] AID - 10.1111/jdv.18263 [doi] PST - ppublish SO - J Eur Acad Dermatol Venereol. 2022 Nov;36(11):1937-1946. doi: 10.1111/jdv.18263. Epub 2022 Jun 9.